Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The stock option was granted as an inducement material to Mr. Strauss’ entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic cell therapies. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Robert H. Uhl
Senior Vice President
Source: Bellicum Pharmaceuticals, Inc.